<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129349</url>
  </required_header>
  <id_info>
    <org_study_id>2009-003</org_study_id>
    <nct_id>NCT01129349</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or&#xD;
      recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and&#xD;
      Maximum Tolerated Dose (MTD) To determine the pharmacokinetics (PK) of Oprozomib To explore&#xD;
      the anti-tumor activity of Oprozomib in this patient population including the overall&#xD;
      response rate (ORR), the duration of responses (DOR), the progression-free survival (PFS) and&#xD;
      time to progression (TTP) To define the pharmacodynamics (PDn) of Oprozomib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open label, dose-escalation study to determine the safety, MTD, and PK/PDn&#xD;
      of Oprozomib when administered orally (PO) on Days 1, 2, 3, 4, and 5 of a 14 day cycle in&#xD;
      patients with advanced refractory or recurrent solid tumor malignancies for which standard&#xD;
      curative measures do not exist or are no longer effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)</measure>
    <time_frame>31 months</time_frame>
    <description>To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)&#xD;
To determine the pharmacokinetics (PK) of Oprozomib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR), duration of responses (DOR), progression-free survival (PFS), and time to progression (TTP)</measure>
    <time_frame>31 months</time_frame>
    <description>To explore the anti-tumor activity of Oprozomib in this patient population including the overall response rate (ORR), the duration of responses (DOR), the progression-free survival (PFS) and time to progression (TTP)&#xD;
To define the pharmacodynamics (PDn) of Oprozomib.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Oprozomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I, Dose Escalation, Single Arm, Open Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oprozomib</intervention_name>
    <description>Oral administration of Oprozomib on Days 1-5 of a 14 day cycle</description>
    <arm_group_label>Oprozomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Histologically confirmed advanced solid tumor that is refractory or recurrent&#xD;
                  after standard treatments.&#xD;
&#xD;
               -  At least one site of radiographically measurable disease of ≥ 2 cm in the largest&#xD;
                  dimension by traditional computed tomography (CT) scanning technique or ≥ 1 cm in&#xD;
                  the largest dimension by spiral CT scanning (per RECIST criteria); or if, in the&#xD;
                  Principal Investigator's opinion, evaluable disease can be reliably and&#xD;
                  consistently followed, the patient may be eligible upon approval by the Onyx&#xD;
                  Therapeutics, Inc., Medical Monitor.&#xD;
&#xD;
          -  Demographic&#xD;
&#xD;
               -  Males and females ≥ 18 years of age&#xD;
&#xD;
               -  Life expectancy of more than three months&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2&#xD;
&#xD;
          -  Laboratory&#xD;
&#xD;
               -  Adequate hepatic function, with bilirubin ≤ 1.5 times the upper limit of normal&#xD;
                  (ULN), and alanine aminotransferase (ALT) ≤ 3 times ULN or ≤ 5 times ULN in the&#xD;
                  presence of hepatic tumor involvement&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/mm3, hemoglobin ≥ 8 g/dL, and platelet&#xD;
                  count ≥ 100,000/ mm3&#xD;
&#xD;
                    1. Screening platelet count must be independent of platelet transfusions for at&#xD;
                       least one week&#xD;
&#xD;
                    2. Screening ANC must be independent of granulocyte- and granulocyte/macrophage&#xD;
                       colony stimulating factor (G-CSF and GM-CSF) support for at least one week&#xD;
                       and of pegylated G-CSF for at least two weeks&#xD;
&#xD;
                    3. Patients may receive red blood cell (RBC) transfusions or receive supportive&#xD;
                       care with erythropoietin or darbepoetin in accordance with institutional&#xD;
                       guidelines&#xD;
&#xD;
               -  Calculated or measured creatinine clearance of ≥ 30 mL/min; calculation using a&#xD;
                  generally accepted formula such as that of Cockcroft and Gault: CrCl = [(140 -&#xD;
                  Age) × Mass (kg) / (72 × Creatinine mg/dL)], multiply by 0.85 if female&#xD;
&#xD;
          -  Ethical / Other&#xD;
&#xD;
               -  Written informed consent in accordance with federal, local, and institutional&#xD;
                  guidelines&#xD;
&#xD;
               -  Female patients of childbearing potential must have a negative serum or urine&#xD;
                  pregnancy test within three days of the first dose and agree to use dual methods&#xD;
                  of contraception during the study and for one month following the last dose of&#xD;
                  study drug. Post-menopausal females (&gt; 45 years old and without menses for &gt; 1&#xD;
                  year) and surgically sterilized females are exempt from these requirements. Male&#xD;
                  patients must use an effective barrier method of contraception during the study&#xD;
                  and for one month following the last dose if sexually active with a female of&#xD;
                  childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Chemotherapy with approved or investigational anticancer therapeutics, including&#xD;
                  steroid therapy, within four weeks prior to first dose of Oprozomib or six weeks&#xD;
                  for antibody therapy&#xD;
&#xD;
               -  Radiation therapy or immunotherapy within three weeks prior to first dose;&#xD;
                  localized radiation therapy within one week prior to first dose Patients with&#xD;
                  brain metastases (patients with prior brain metastases are permitted, but must&#xD;
                  have completed treatment and have no evidence of active CNS disease for at least&#xD;
                  three months prior to first dose)&#xD;
&#xD;
               -  Prior treatment with a proteasome inhibitor&#xD;
&#xD;
          -  Concurrent Conditions&#xD;
&#xD;
               -  Major surgery within three weeks prior to first dose&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association Class III to IV),&#xD;
                  symptomatic ischemia, or conduction abnormalities. Conduction system&#xD;
                  abnormalities not clinically warranting intervention are allowed.&#xD;
&#xD;
               -  Myocardial infarction within three months prior to first dose&#xD;
&#xD;
               -  Active infection requiring systemic antibiotics, antivirals, or antifungals&#xD;
                  within two weeks prior to first dose&#xD;
&#xD;
               -  HIV infection (HIV seropositive)&#xD;
&#xD;
               -  Active hepatitis A, B, or C infection&#xD;
&#xD;
               -  Peripheral neuropathy of Grade ≥ 3 or Grade 2 with pain at the time of the first&#xD;
                  dose&#xD;
&#xD;
               -  Patients with pleural effusions requiring repeat thoracentesis or ascites&#xD;
                  requiring repeat paracentesis&#xD;
&#xD;
               -  Prior Oprozomib therapy&#xD;
&#xD;
               -  Hypersensitivity to Oprozomib or any of its components&#xD;
&#xD;
          -  Ethical / Other&#xD;
&#xD;
               -  Female patients who are pregnant or lactating&#xD;
&#xD;
               -  Psychiatric or medical conditions that in the opinion of the Investigator could&#xD;
                  interfere with treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Research Associates</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

